/
ABBV
$255.82-$5.89 (-2.24%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$454.8B
1,767M shares
52-week range
$187.62 – $267.47
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Change+$141.96
ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
www.abbvie.com- Employees
- 57,000
- IPO / List date
- Dec 10, 2012
- HQ
- NORTH CHICAGO, IL
Held by traders on TradeandTell
No one on the platform currently holds ABBV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 928,071 | $214.9M |
| Bridgewater Associatesas of 2026-03-31 | 30,362 | $6.6M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 2.67% ($6.83/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-15 | $1.7300 | 2026-08-14 |
| 2026-04-15 | $1.7300 | 2026-05-15 |
| 2026-01-16 | $1.7300 | 2026-02-17 |
| 2025-10-15 | $1.6400 | 2025-11-14 |
| 2025-07-15 | $1.6400 | 2025-08-15 |
| 2025-04-15 | $1.6400 | 2025-05-15 |
| 2025-01-15 | $1.6400 | 2025-02-14 |
| 2024-10-15 | $1.5500 | 2024-11-15 |
| 2024-07-15 | $1.5500 | 2024-08-15 |
| 2024-04-12 | $1.5500 | 2024-05-15 |
Recent trades on TradeandTell
No one on the platform has traded ABBV yet.
